TOKYO (Reuters) - Fujifilm Holdings Corp said on Wednesday its Avigan drug reduced viral loads and symptoms of COVID-19 patients, paving the way for regulatory approval in Japan after months of delays.
The Phase 3 clinical study of 156 patients showed that those treated with Avigan improved after 11.9 days, versus 14.
7 days for a placebo group. Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant, the company said in a release.
Former Japanese Prime Minister Shinzo Abe had touted Avigan's.